SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.
Infinity Pharmaceuticals lays off 78% of staff, shrinks board after MEI merger fail
Infinity Pharmaceuticals is scrambling to reduce its “burn rate” after the proposed merger with MEI Pharma fell through, turning to layoffs and a downsized board